The test developed by Alcediag could potentially reduce the diagnostic timeline for bipolar disorder from years to weeks, offering hope for more accurate diagnoses.
'There is a role for investigating biomarkers,' states psychiatrist Suresh Sundram, highlighting the promise yet challenges of using biomarkers for mental health diagnoses.
Alcediag's EDIT-B blood test aims to differentiate bipolar disorder from depression using RNA editing biomarkers, although some researchers question trial sizes and validity.
With around 40 million people living with bipolar disorder globally, the lengthy diagnostic process often results in misdiagnoses, pointing to the need for faster, effective solutions.
Collection
[
|
...
]